|19th October 2020||Mark Alan Goldberg||5,455||Exercise of derivative||$19.53||$106,536.15|
|19th October 2020||Mark Alan Goldberg||5,455||Open or private sale||$105.00||$572,775.00|
|16th October 2020||Kate Haviland||3,125||Open or private sale||$101.56||$317,375.00|
|16th October 2020||Kate Haviland||13,334||Exercise of derivative||$36.05||$480,690.70|
|16th October 2020||Kate Haviland||3,009||Open or private sale||$102.53||$308,512.77|
|16th October 2020||Kate Haviland||7,200||Open or private sale||$100.55||$723,960.00|
|7th October 2020||Jeffrey W. Albers||5,000||Open or private sale||$99.17||$495,850.00|
|7th October 2020||Jeffrey W. Albers||5,000||Exercise of derivative||$8.80||$44,000.00|
|7th October 2020||Mark Alan Goldberg||5,454||Open or private sale||$100.00||$545,400.00|
|7th October 2020||Mark Alan Goldberg||5,454||Exercise of derivative||$19.53||$106,516.62|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Blueprint Medicines Corp. focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in 2008.